Table 1.
Baseline demographics, smoking status, and laboratorial data in patients with subocclusive ileocecal Crohn’s disease according to therapy with azathioprine or mesalazine.
| Characteristics | Azathioprine group (n=36) | Mesalazine group (n = 36) | P value |
|---|---|---|---|
| Gender (F/M) (n) | 18/18 | 19/17 | 0.81 |
| Age (yr)* | 36±12 | 38±12.6 | 0.49 |
| Age <40 yr (n) | 25 | 19 | 0.14 |
| Smokers (n) | 5 | 4 | 0.87 |
| Disease duration (yr)* | 5.8±2.9 | 5.9±2.7 | 0.91 |
| C-reactive protein (mg/L)* | 20±17.9 | 18.6±17.3 | 0.74 |
| ESR** (mm/h)* | 10.4±4.5 | 10.1±4 | 0.73 |
| Platelet count (mm3)* | 308,732±69,070 | 301,583±71,334 | 0.67 |
*
mean ±SD;
**
ESR – erythrocyte sedimentation rate.